

HEALTH PLAN POLICY	
Policy Title: Gene Expression Profiling for Coronary Artery Disease	Policy Number: MUM55 Revision: B
Department: Medical Management	Sub-Department: Utilization Management
Applies to Product Lines: <input type="checkbox"/> Medicaid <input checked="" type="checkbox"/> USFHP <input type="checkbox"/> Children’s Health Insurance Plan <input checked="" type="checkbox"/> Commercial Insured <input checked="" type="checkbox"/> Health Insurance Exchange <input type="checkbox"/> Non Insured Business <input checked="" type="checkbox"/> Medicare	
Origination/Effective Date: 10/09/2019	
Reviewed Date(s):	Revision Date(s): 08/26/2020, 08/17/2021

SCOPE:

This policy addresses genetic expression profiling (GEP) for patients with coronary artery disease (CAD).

DEFINITIONS AND ACRONYMS:

- **Communicable Disease Center (CDC)**
- **Coronary Artery Disease (CAD)**
- **Gene Expression Profiling (GEP)**

POLICY:

GEP for CAD is investigational and not medically necessary.

RATIONALE:

CAD accounts for 370,000 deaths per year. The gold standard for diagnostic purposes is coronary angiography. This is an invasive procedure that increases risk. In an effort to decrease procedural risk, GEP is a non-invasive technique employed rather than angiography.

There is a commercially available test – Corus CAD. This test is not FDA approved. The test is somewhat limited in its application given it can only be used in non-diabetics. CAD has a high degree of association with diabetes. Although Corus CAD has some diagnostic value, there is no literature based evidence indicating improve clinical outcomes. Several other non-invasive studies are available to assist physicians in identifying CAD.

REFERENCES:

- CDC 2017 – Differences in Women Compared to Men Relative to CAD
- CDC 2015 – Symptoms of CAD
- Ayerbe 2016 – Validated Risk Prediction Tools

HEALTH PLAN POLICY

Policy Title: Gene Expression Profiling for Coronary Artery Disease

Policy Number: MUM55
Revision: B

RELATED DOCUMENTS:

None

REVISION HISTORY:

Revision	Date	Description of Change	Committee
New	10/09/2019	Initial release.	Executive Leadership
A	08/26/2020	Yearly review. No change to policy content.	Executive Leadership
B	08/17/2021	Yearly review. No change to policy content.	Executive Leadership